It’s not too late .... Contact your Senators and your

New Post Public Reply Private Reply Replies (0) Message Board
CyberC Hate Liars #51576
517
It’s not too late .... Contact your Senators and your Congressman concerning their work on the misuse of the 101. Both are working on their own Bills to reform the 101
Great news today for our patent fight!

Senate IP Subcommittee Hears Testimony from Iancu, Debates IP Issues
By Steve Brachmann
March 20, 2019
www.ipwatchdog.com/2019/03/20/senate-ip-subcommittee-hears-testimony-iancu-debates-ip-issues/id=107468/

“Iancu said that, while it was important to prevent abuse in the system, he took issue with the use of pejorative terms like ‘patent troll’ that fail to identify specific issues that could be solved.”

https://www.senate.gov/artandhistory/art/comm...0503.htmOn the afternoon of Wednesday, March 13, the Senate Judiciary Committee’s Subcommittee on Intellectual Property held an oversight hearing of the U.S. Patent and Trademark Office featuring testimony from and questioning of USPTO Director Andrei Iancu. While this hearing was relatively short by Congressional standards, the Senate IP Subcommittee explored recent changes instituted during Iancu’s tenure as USPTO Director and also got into the debate on pharmaceutical patents—a topic that has been front and center for both houses of Congress in recent weeks.

Chairman Tillis, Ranking Member Coons Encouraged by Subject Matter Eligibility Guidance

In his opening statement, Senate IP Subcommittee Chairman Sen. Thom Tillis (R-NC) expressed his support of Director Iancu’s efforts to harmonize the clam construction standard utilized in America Invents Act (AIA) trials occurring at the Patent Trial and Appeal Board (PTAB) with the Phillips construction standard used in Article III federal courts , adding that this helped to ensure that patent owners were being treated fairly regardless of the forum where validity was being challenged. Tillis also said he was “glad to see” the USPTO issue revised guidance on subject matter eligibility under the Alice/Mayo framework, a framework that Tillis noted had created massive uncertainty for every industry that relies on patents . Although Tillis expressed concerns about the legacy tech systems still being used at the USPTO, he added that he was encouraged by Iancu’s efforts to make modernization at the agency a priority.

Ranking Member Sen. Chris Coons (D-DE) was also supportive of changes made by Iancu since he became the USPTO Director, noting that those changes helped the U.S. patent system rise to tie for 2nd place in the 2019 version of the U.S. Chamber of Commerce’s International IP Index up from its previous position of 12th place. However, Coons expressed his concern that current case law on patent eligibility dis-incentivizes research into critical areas of innovation, such as personalized medicine. Coons acknowledged that the USPTO couldn’t solve this problem on its own and said that efforts were being made to work towards a legislative solution to what he called this “thorny challenge.”

Iancu Highlights Recent Agency Actions in His Testimony

Director Iancu began his statement by highlighting some of the changes implemented at the USPTO, which were covered in more detail in his written testimony, including the change to the Phillips claim construction standard and the recently revised subject matter eligibility guidelines. He expressed his satisfaction with the recent passage of the SUCCESS Act, which extended the fee setting authority of the USPTO for an additional eight years when it was passed into law last October. Under the terms of that law, the USPTO was directed to study and report on the number of patents obtained by women, minorities and veterans, and Iancu pointed to a USPTO report released last month which showed that the number of women named as inventors had not been increasing at the same rate as the number of women who were now in STEM professions. Iancu also discussed a recent notice of proposed rulemaking that would require foreign domiciled trademark applicants to use U.S. licensed counsel—a measure to reduce the number of trademark applications from overseas that are filed in bad faith.

Iancu Discusses Telework, Bad Faith Trademark Applications and Serial PTAB Challenges

Sen. Mazie Hirono questioned Iancu about the USPTO’s Telework Enhancement Act Pilot Program (TEAPP), which in general is very beneficial to the Office but requires teleworking employees stationed in Hawaii to make a monthly trip back to the agency’s headquarters in Alexandria, Virginia. Although the agency was still assessing the technology needed to facilitate teleworkers in Hawaii and Alaska without such commuting requirements, Iancu said that he was hoping to be able to make those changes soon. Hirono also asked about the report on women inventors and asked what steps were being taken to close the gaps shown in that study. Iancu cited a roundtable discussion in Silicon Valley with companies and academics that occurred soon after the report came out to discuss actions that can be taken. Iancu said that he thought one of the most important factors to encourage inventions from women and minority groups was to have appropriate role models and mentors so they can see people like themselves participating in the U.S. patent system. Sen. Tillis followed by noting that the Senate IP Subcommittee would be holding a hearing in April on this particular issue.

Other issues discussed during the hearing included problems with an influx of trademark applications from China, many of which are questionable in nature. Iancu discussed a pilot program recently put in place to expedite trademark cancellations but added that this program was fairly new. He also discussed new software developed for the agency that can help trademark examiners determine whether any specimens of use provided as part of the application have been Photoshopped in any way.

Asked about issues surrounding the current state of Section 101 patent eligibility, which Sen. Coons said continued to preclude significant advances in medical diagnostics, Iancu said that the recently revised subject matter eligibility guidance was well received by examiners, but it remained to see how the courts would interpret it. He cited the Federal Circuit’s recent decision in Athena Diagnostics v. Mayo Collaborative Services where the panel majority felt its hands were tied by Supreme Court precedent despite their belief regarding the importance of the technology . Iancu also answered concerns from Sen. Hirono about serial challenges at the PTAB filed by major firms like Apple or Google, which present a particular hardship for small patent owners. Iancu noted positive results from a revised trial practice guide issued by the USPTO a few months ago and said that the agency would continue to take a further look at situations where multiple petitions challenging the same claims would be inappropriate.

Read More: https://investorshangout.com/post/view?id=538...z5ik0os6G1

Zerify Inc (ZRFY) Stock Research Links

ZRFY Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

IntelliGenome Partners with NL Diagnóstica for TB Battle

Updated Category News Views 133

Breaking New Ground in Tuberculosis Detection When IntelliGenome, a Houston-based developer of CRISPR-based diagnostic tech, teams up with São Paulo's veteran player NL Diagnóstica, you know they're onto something game-changing. This partnership is all about taking the fight against tuberculosis in Brazil to new heights with their CRISPR-Dx™ diagnostic platform. Not...

Continue Reading
Tennessee Highlights Alarming COPD Rates This November

Updated Category News Views 49

Tennessee Turns the Spotlight on COPD Here we are again, looking at Tennessee with its weary lung health woes. Governor Bill Lee's newest proclamation for November as COPD Awareness Month is shining a light on a crisis that's been disproportionately hitting the state harder than a sideswipe from a semi. Why the Proclamation Matters Let's cut through the fog—COPD,...

Continue Reading
Fresha Teams with Klarna: Shaking Up Beauty Payments

Updated Category News Views 126

New Flexibility at the Beauty Checkout Hey, if you've ever paced back and forth considering signing up for that luxury self-care spree, well, Fresha’s latest move might just tip the scales. The beauty and wellness booking giant has partnered with Klarna, diving headfirst into the Buy Now, Pay Later (BNPL) craze. It's about time, right? Everyone loves a good spa session,...

Continue Reading
Emergys and Glean Rearrange AI Puzzle for Enterprises

Updated Category News Views 132

Enterprises on AI: From Dreams to Doing Alright, here’s a nugget for you: AI isn't just pie-in-the-sky jazz anymore. Some folks are finally bringing it down to Earth. Emergys, a player in digital transformation, is shaking hands with Glean, renowned for their enterprise AI chops, to turn enterprise chaos into clarity. It's all about squeezing out real returns and...

Continue Reading
Consumer Electronics Boom: Profits Soar Till 2035

Updated Category News Views 0

Riding the Electronics Tsunami The consumer electronics sector isn't just catching a wave; it's barreling through a technological tsunami. Projected to leap from USD 1100.87 billion in 2026 to USD 2825.55 billion by 2035, we're talking a whopping 11.04% CAGR. It's driven by none other than the smartphone frenzy, intelligent computing advances, and the almighty connected...

Continue Reading
Exploring 'Deeper Prayer': A Journey with Apostle Paul

Updated Category News Views 143

A Deep Dive into the Prayers of Apostle Paul Gary P. Rohrmayer's latest devotional takes believers on a unique journey, exploring the Apostle Paul's prayers across his missionary paths. But don't expect just another preacher prophesying from the pulpit. This is more like peeling back layers of history, bit by bit. 28 Days of Spiritual Insights Each day within the book...

Continue Reading
Northwind Backs Huge Office-to-Residential Overhaul

Updated Category News Views 172

In the Heart of Midtown: A Major Overhaul I'm telling ya, if there's a piece of news that makes me sit up straight this morning over the breakfast bar, it's this colossal $231 million construction loan announcement by Northwind Group. They're turning 675 Third Avenue, a towering 32-story office behemoth smack in Midtown, into residential apartments. Right here in...

Continue Reading
Potomac Edison Targets Virginia Grid Revamp by 2030

Updated Category News Views 82

Strengthening the Backbone of Virginia's Power Supply Ever had your lights flicker on a windy day and wondered if the power grid would hold? Potomac Edison, under the banner of FirstEnergy Corp., is stepping up with a game plan to fortify the electric spine of Virginia and its neighbors. They're diving into a multi-state adventure, rebuilding and erecting 138 kV...

Continue Reading
Magnolia's Data Breach Raises Eyebrows and Concerns

Updated Category News Views 84

Data Security Breach: Today's Digital Nightmare In the relentless digital jungle we live in, someone’s email account is like a treasure trove for cybercriminals sniffing around for their next haul. And that’s precisely what went down at Magnolia Management Company, LLC out in East Longmeadow, Massachusetts. It was April 3, 2026, when they stumbled upon some...

Continue Reading
Vantage's Pre-IPO CFD: New Frontier or Gamble?

Updated Category News Views 146

Ah, the thrill of the pre-IPO buzz. Vantage has thrown its hat into the ring with a pre-IPO CFD offering, giving stock jockeys like you and me a chance to express our bullish or bearish convictions before a company goes public. The question is: does this open new doors for the sharp-eyed investor, or are we just adding another layer of risk onto an already wild ride?...

Continue Reading

Top 5 Most Recently Viewed Articles

Legal Action Review for Lineage, Inc. Investors - Take Note

Updated Category News Views 122

Overview of Legal Issues Facing Lineage, Inc. Investors should be aware of important developments regarding Lineage, Inc. This leading company is currently facing a class action securities lawsuit. This news has garnered attention as it deeply impacts shareholders and signifies the need for vigilance within the investment community. What is the Class Action Lawsuit About?...

Continue Reading
Midnight Hub Investors Urged to Act on Class Action Opportunity

Updated Category News Views 102

Investors Alert: Class Action Lawsuit Opportunity for Midnight Hub NFT Holders In a significant development for investors affiliated with Midnight Hub, Bronstein, Gewirtz & Grossman, LLC has formally announced a riveting class action lawsuit directed at individuals who acquired ROOMS non-fungible tokens (NFTs) and Digital Nomads NFTs. These digital assets, issued by...

Continue Reading
Exploring the Synergy of AI and Blockchain in Finance

Updated Category News Views 229

The Transformative Power of AI and Blockchain In the rapidly evolving world of finance, the integration of artificial intelligence (AI) and blockchain technology is heralding a new era. As digital markets expand, the sheer volume and speed of data can be overwhelming for traditional processing methods. This is where artificial intelligence steps in, restructuring...

Continue Reading
TeraWatt Tech Snags Battery Vet Dr. Kang for Innovation Boost

Updated Category News Views 5

Next Big Leap in Battery Tech? Dr. Sunho Kang's arrival at TeraWatt Technology is the kind of news that makes folks in the energy sector sit up and take notice. With more than 25 years under his belt handling battery innovations from lab to factory floor, Kang's move smells like a game-changer for TeraWatt. If you don't know already, TeraWatt’s not just dabbling in...

Continue Reading
Nuvation Bio's Upcoming Results: Trading the Oncology Gamble?

Updated Category News Views 166

Nuvation Bio Inc. (NYSE: NUVB) is set to drop its financial results for Q4 and the full year of 2025 on March 2, 2026. Mark your calendars—this one could be a rollercoaster ride for traders. The oncology firm’s got a diversified pipeline packed with heavy-hitters like taletrectinib and safusidenib, but the real question is whether these treatments will convert into...

Continue Reading